Do analysts recommend SLGL or DRCT?

Sol-Gel Technologies presently has a consensus target price of $197.50, indicating a potential upside of 230.77%. Given Sol-Gel Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Sol-Gel Technologies is more favorable than Direct Digital. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sol-Gel Technologies 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67 Direct Digital 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor SLGL or TRAW?

In the previous week, Sol-Gel Technologies and Sol-Gel Technologies both had 2 articles in the media. Sol-Gel Technologies' average media sentiment score of 0.90 beat Traws Pharma's score of 0.00 indicating that Sol-Gel Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sol-Gel Technologies 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Traws Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor SLGL or COLL?

In the previous week, Collegium Pharmaceutical had 5 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 7 mentions for Collegium Pharmaceutical and 2 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 0.90 beat Collegium Pharmaceutical's score of -0.22 indicating that Sol-Gel Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sol-Gel Technologies 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Collegium Pharmaceutical 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PHAT or SLGL?

In the previous week, Phathom Pharmaceuticals had 3 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 5 mentions for Phathom Pharmaceuticals and 2 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 0.90 beat Phathom Pharmaceuticals' score of -0.35 indicating that Sol-Gel Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phathom Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Sol-Gel Technologies 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Sol-Gel Technologies (SLGL) Competitors

$59.71 -1.24 (-2.03%)

Closing price 04:00 PM Eastern

Extended Trading

$59.60 -0.11 (-0.18%)

As of 04:10 PM Eastern

Compare

SLGL vs. DRCT, TRAW, COLL, ZVRA, and PHAT

Should you buy Sol-Gel Technologies stock or one of its competitors? Sol-Gel Technologies's main competitors and comparable companies include Direct Digital (DRCT), Traws Pharma (TRAW), Collegium Pharmaceutical (COLL), Zevra Therapeutics (ZVRA), and Phathom Pharmaceuticals (PHAT). Companies are selected based on similarities in market, industry, and size.

How does Sol-Gel Technologies compare to Direct Digital?

Sol-Gel Technologies (NASDAQ:SLGL) and Direct Digital (NASDAQ:DRCT) are related small-cap companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

26.2% of Sol-Gel Technologies shares are owned by institutional investors. Comparatively, 4.0% of Direct Digital shares are owned by institutional investors. 66.5% of Sol-Gel Technologies shares are owned by company insiders. Comparatively, 25.6% of Direct Digital shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Sol-Gel Technologies presently has a consensus target price of $197.50, indicating a potential upside of 230.77%. Given Sol-Gel Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Sol-Gel Technologies is more favorable than Direct Digital.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Direct Digital	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Direct Digital has a net margin of -74.38% compared to Sol-Gel Technologies' net margin of -910.14%. Direct Digital's return on equity of 0.00% beat Sol-Gel Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sol-Gel Technologies	-910.14%	-44.05%	-36.96%
Direct Digital	-74.38%	N/A	-68.48%

In the previous week, Sol-Gel Technologies had 2 more articles in the media than Direct Digital. MarketBeat recorded 2 mentions for Sol-Gel Technologies and 0 mentions for Direct Digital. Sol-Gel Technologies' average media sentiment score of 0.90 beat Direct Digital's score of 0.00 indicating that Sol-Gel Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Sol-Gel Technologies	Positive
Direct Digital	Neutral

Sol-Gel Technologies has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market. Comparatively, Direct Digital has a beta of 5.3, indicating that its stock price is 430% more volatile than the broader market.

Sol-Gel Technologies has higher earnings, but lower revenue than Direct Digital. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Direct Digital, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sol-Gel Technologies	$1.80M	93.47	-$6.13M	-$5.64	N/A
Direct Digital	$34.69M	0.04	-$18.95M	-$156.85	N/A

Summary

Sol-Gel Technologies beats Direct Digital on 12 of the 17 factors compared between the two stocks.

How does Sol-Gel Technologies compare to Traws Pharma?

Sol-Gel Technologies (NASDAQ:SLGL) and Traws Pharma (NASDAQ:TRAW) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.

Traws Pharma has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -910.14%. Sol-Gel Technologies' return on equity of -44.05% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sol-Gel Technologies	-910.14%	-44.05%	-36.96%
Traws Pharma	N/A	-23,868.92%	-165.52%

In the previous week, Sol-Gel Technologies and Sol-Gel Technologies both had 2 articles in the media. Sol-Gel Technologies' average media sentiment score of 0.90 beat Traws Pharma's score of 0.00 indicating that Sol-Gel Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sol-Gel Technologies	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Traws Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sol-Gel Technologies has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market. Comparatively, Traws Pharma has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market.

26.2% of Sol-Gel Technologies shares are owned by institutional investors. Comparatively, 8.0% of Traws Pharma shares are owned by institutional investors. 66.5% of Sol-Gel Technologies shares are owned by insiders. Comparatively, 7.6% of Traws Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Traws Pharma has higher revenue and earnings than Sol-Gel Technologies. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sol-Gel Technologies	$1.80M	93.47	-$6.13M	-$5.64	N/A
Traws Pharma	$2.79M	2.77	$9.17M	-$1.74	N/A

Sol-Gel Technologies currently has a consensus price target of $197.50, indicating a potential upside of 230.77%. Traws Pharma has a consensus price target of $1.00, indicating a potential upside of 98.57%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, equities analysts clearly believe Sol-Gel Technologies is more favorable than Traws Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Traws Pharma	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

Sol-Gel Technologies beats Traws Pharma on 10 of the 16 factors compared between the two stocks.

How does Sol-Gel Technologies compare to Collegium Pharmaceutical?

Sol-Gel Technologies (NASDAQ:SLGL) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

26.2% of Sol-Gel Technologies shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Sol-Gel Technologies presently has a consensus target price of $197.50, indicating a potential upside of 230.77%. Collegium Pharmaceutical has a consensus target price of $48.71, indicating a potential upside of 116.99%. Given Sol-Gel Technologies' stronger consensus rating and higher probable upside, equities research analysts plainly believe Sol-Gel Technologies is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Collegium Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

In the previous week, Collegium Pharmaceutical had 5 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 7 mentions for Collegium Pharmaceutical and 2 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 0.90 beat Collegium Pharmaceutical's score of -0.22 indicating that Sol-Gel Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sol-Gel Technologies	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Collegium Pharmaceutical	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Collegium Pharmaceutical has a net margin of 5.93% compared to Sol-Gel Technologies' net margin of -910.14%. Collegium Pharmaceutical's return on equity of 91.43% beat Sol-Gel Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sol-Gel Technologies	-910.14%	-44.05%	-36.96%
Collegium Pharmaceutical	5.93%	91.43%	15.57%

Collegium Pharmaceutical has higher revenue and earnings than Sol-Gel Technologies. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sol-Gel Technologies	$1.80M	93.47	-$6.13M	-$5.64	N/A
Collegium Pharmaceutical	$780.57M	0.94	$62.87M	$1.24	18.10

Sol-Gel Technologies has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market.

Summary

Collegium Pharmaceutical beats Sol-Gel Technologies on 9 of the 17 factors compared between the two stocks.

How does Sol-Gel Technologies compare to Zevra Therapeutics?

Zevra Therapeutics (NASDAQ:ZVRA) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

Zevra Therapeutics currently has a consensus price target of $27.14, indicating a potential upside of 139.78%. Sol-Gel Technologies has a consensus price target of $197.50, indicating a potential upside of 230.77%. Given Sol-Gel Technologies' higher probable upside, analysts clearly believe Sol-Gel Technologies is more favorable than Zevra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Zevra Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. Comparatively, Sol-Gel Technologies has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market.

In the previous week, Sol-Gel Technologies had 2 more articles in the media than Zevra Therapeutics. MarketBeat recorded 2 mentions for Sol-Gel Technologies and 0 mentions for Zevra Therapeutics. Sol-Gel Technologies' average media sentiment score of 0.90 beat Zevra Therapeutics' score of 0.00 indicating that Sol-Gel Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Zevra Therapeutics	Neutral
Sol-Gel Technologies	Positive

Zevra Therapeutics has a net margin of 42.82% compared to Sol-Gel Technologies' net margin of -910.14%. Zevra Therapeutics' return on equity of 54.54% beat Sol-Gel Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	42.82%	54.54%	34.15%
Sol-Gel Technologies	-910.14%	-44.05%	-36.96%

Zevra Therapeutics has higher revenue and earnings than Sol-Gel Technologies. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$106.47M	6.31	$83.23M	$0.92	12.30
Sol-Gel Technologies	$1.80M	93.47	-$6.13M	-$5.64	N/A

35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are held by institutional investors. 3.7% of Zevra Therapeutics shares are held by company insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Zevra Therapeutics beats Sol-Gel Technologies on 10 of the 17 factors compared between the two stocks.

How does Sol-Gel Technologies compare to Phathom Pharmaceuticals?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings, dividends and media sentiment.

In the previous week, Phathom Pharmaceuticals had 3 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 5 mentions for Phathom Pharmaceuticals and 2 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 0.90 beat Phathom Pharmaceuticals' score of -0.35 indicating that Sol-Gel Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phathom Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sol-Gel Technologies	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Phathom Pharmaceuticals has a net margin of -41.34% compared to Sol-Gel Technologies' net margin of -910.14%. Phathom Pharmaceuticals' return on equity of 0.00% beat Sol-Gel Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-41.34%	N/A	-20.81%
Sol-Gel Technologies	-910.14%	-44.05%	-36.96%

Phathom Pharmaceuticals currently has a consensus target price of $21.25, indicating a potential upside of 204.01%. Sol-Gel Technologies has a consensus target price of $197.50, indicating a potential upside of 230.77%. Given Sol-Gel Technologies' higher possible upside, analysts plainly believe Sol-Gel Technologies is more favorable than Phathom Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Sol-Gel Technologies has lower revenue, but higher earnings than Phathom Pharmaceuticals. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	3.23	-$221.25M	-$1.28	N/A
Sol-Gel Technologies	$1.80M	93.47	-$6.13M	-$5.64	N/A

Phathom Pharmaceuticals has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market. Comparatively, Sol-Gel Technologies has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market.

99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are owned by institutional investors. 9.3% of Phathom Pharmaceuticals shares are owned by insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Phathom Pharmaceuticals beats Sol-Gel Technologies on 10 of the 16 factors compared between the two stocks.

Get Sol-Gel Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLGL vs. The Competition

Export

Metric	Sol-Gel Technologies	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$171.26M	$12.40B	$7.20B	$13.10B
Dividend Yield	N/A	2.63%	2.53%	12.99%
P/E Ratio	-10.59	794.80	274.58	25.69
Price / Sales	93.47	830.44	647.39	85.37
Price / Cash	N/A	86.22	76.31	52.02
Price / Book	7.29	10.62	10.44	6.32
Net Income	-$6.13M	$2.81B	$3.49B	$359.73M
7 Day Performance	-5.88%	0.73%	0.53%	1.35%
1 Month Performance	-23.18%	-1.67%	-3.36%	-3.68%
1 Year Performance	104.84%	3.06%	16.04%	5.56%

Sol-Gel Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLGL Sol-Gel Technologies	3.409 of 5 stars	$59.71 -2.0%	$197.50 +230.8%	+117.6%	$171.26M	$1.80M	N/A	28
DRCT Direct Digital	0.9797 of 5 stars	$2.08 +13.7%	N/A	-97.9%	$1.67M	$30.91M	N/A	60	Positive News
TRAW Traws Pharma	1.3288 of 5 stars	$0.53 +1.9%	$1.00 +89.0%	-73.8%	$8.13M	$2.79M	N/A	17	News Coverage Positive News
COLL Collegium Pharmaceutical	3.0394 of 5 stars	$21.84 -4.3%	$48.50 +122.1%	-36.1%	$711.11M	$780.57M	17.61	423	News Coverage Analyst Forecast
ZVRA Zevra Therapeutics	4.1815 of 5 stars	$11.65 -3.3%	$27.14 +133.0%	+45.7%	$691.82M	$136.07M	12.66	61

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLGL) was last updated on 9/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sol-Gel Technologies (SLGL) Competitors

SLGL vs. DRCT, TRAW, COLL, ZVRA, and PHAT

How does Sol-Gel Technologies compare to Direct Digital?

Summary

How does Sol-Gel Technologies compare to Traws Pharma?

Summary

How does Sol-Gel Technologies compare to Collegium Pharmaceutical?

Summary

How does Sol-Gel Technologies compare to Zevra Therapeutics?

Summary

How does Sol-Gel Technologies compare to Phathom Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLGL vs. The Competition

Sol-Gel Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sol-Gel Technologies (SLGL) Competitors

SLGL vs. DRCT, TRAW, COLL, ZVRA, and PHAT

How does Sol-Gel Technologies compare to Direct Digital?

Do institutionals and insiders believe in SLGL or DRCT?

Do analysts recommend SLGL or DRCT?

Is SLGL or DRCT more profitable?

Does the media favor SLGL or DRCT?

Which has more risk & volatility, SLGL or DRCT?

Which has better valuation & earnings, SLGL or DRCT?

Summary

How does Sol-Gel Technologies compare to Traws Pharma?

Is SLGL or TRAW more profitable?

Does the media favor SLGL or TRAW?

Which has more volatility & risk, SLGL or TRAW?

Do insiders and institutionals believe in SLGL or TRAW?

Which has higher earnings and valuation, SLGL or TRAW?

Do analysts recommend SLGL or TRAW?

Summary

How does Sol-Gel Technologies compare to Collegium Pharmaceutical?

Do insiders & institutionals believe in SLGL or COLL?

Do analysts recommend SLGL or COLL?

Does the media favor SLGL or COLL?

Is SLGL or COLL more profitable?

Which has preferable valuation and earnings, SLGL or COLL?

Which has more volatility and risk, SLGL or COLL?

Summary

How does Sol-Gel Technologies compare to Zevra Therapeutics?

Do analysts recommend ZVRA or SLGL?

Which has more risk & volatility, ZVRA or SLGL?

Does the media favor ZVRA or SLGL?

Is ZVRA or SLGL more profitable?

Which has stronger earnings & valuation, ZVRA or SLGL?

Do insiders and institutionals believe in ZVRA or SLGL?

Summary

How does Sol-Gel Technologies compare to Phathom Pharmaceuticals?

Does the media refer more to PHAT or SLGL?

Is PHAT or SLGL more profitable?

Do analysts rate PHAT or SLGL?

Which has higher earnings & valuation, PHAT or SLGL?

Which has more volatility and risk, PHAT or SLGL?

Do institutionals & insiders have more ownership in PHAT or SLGL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLGL vs. The Competition

Sol-Gel Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools